The fact that such mutations correlate with better prognosis specifically in patients whose tumors have relatively low sGSN transcript levels suggests that local production of sGSN in the TME may be a means of evading DNGR-1-dependent induction of anti-tumor immunity irrespective of plasma sGSN levels. This evidence concerns the gene CLEC9A and neoplasm.